These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2444745)

  • 21. [Antithrombin III activity in long-developing hypercoagulation in animals].
    Pastorova VE; Bazaz'ian GG; Liapina LA
    Biull Eksp Biol Med; 1984 Nov; 98(11):560-3. PubMed ID: 6509173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antithrombin III: critical review of the methods used for its monitoring in thrombophilic states].
    Modiano A; Belisario A
    G Clin Med; 1981 Sep; 62(9):597-608. PubMed ID: 7033027
    [No Abstract]   [Full Text] [Related]  

  • 23. [Renal pathology in the Ivory Coast: exploration and functional activity of antithrombin iii].
    Blavy G; Kouame C
    Nephrologie; 1994; 15(6):387-9. PubMed ID: 7862227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of antithrombin III microheterogeneity.
    Milner AE; Burnett D; Rutter J; Bradwell AR
    Thromb Res; 1985 Jan; 37(1):127-34. PubMed ID: 3983894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permeability of a heparin-polyvinyl alcohol hydrogel to thrombin and antithrombin III.
    Smith BA; Sefton MV
    J Biomed Mater Res; 1988 Aug; 22(8):673-85. PubMed ID: 3215905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of antithrombin III in kidney diseases].
    Schrader J; Köstering H; Scheler F
    Behring Inst Mitt; 1986 Feb; (79):216-30. PubMed ID: 3718408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombin neutralization by antithrombin III depending upon the intensity of thrombin-formation in experimental and clinical surgical interventions].
    Pastorova VE; Tabakina TE; Ivanov AIu
    Vopr Med Khim; 1986; 32(5):28-32. PubMed ID: 3776113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome (Heymann nephritis).
    Girot R; Jaubert F; Leon M; Bellon B; Aiach M; Josso F; Lepelletier O; Beguin S; Monnet JP
    Thromb Haemost; 1983 Feb; 49(1):13-7. PubMed ID: 6601862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Identification of antithrombin III in human aqueous humor (author's transl)].
    Schmut O; Hofmann H
    Albrecht Von Graefes Arch Klin Exp Ophthalmol; 1979 May; 210(3):219-21. PubMed ID: 116567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombin III loss in patients with nephrotic syndrome or receiving continuous ambulatory peritoneal dialysis. Evidence of inactive antithrombin III in urine of patients with nephrotic syndrome.
    De Stefano V; Triolo L; De Martini D; Ferrelli R; Mori R; Leone G
    J Lab Clin Med; 1987 May; 109(5):550-5. PubMed ID: 3572202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High plasma levels of protein C activity and antigen in the nephrotic syndrome.
    Mannucci PM; Valsecchi C; Bottasso B; D'Angelo A; Casati S; Ponticelli C
    Thromb Haemost; 1986 Feb; 55(1):31-3. PubMed ID: 3754658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigenic changes produced by complex formation between thrombin and antithrombin-III.
    McDuffie FC; Peterson JM; Clark G; Mann KG
    J Immunol; 1981 Jul; 127(1):239-44. PubMed ID: 6787123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk factors, atherosclerosis and thromboembolism in the nephrotic syndrome].
    Previato G; Loschiavo C; Tessitore N; Chiaramonte S; Oldrizzi L; Lupo A; Valvo E; Maschio G; Saporiti E
    Minerva Nefrol; 1981; 28(3):421-30. PubMed ID: 7036020
    [No Abstract]   [Full Text] [Related]  

  • 36. Antithrombin III determination by rate (kinetic) nephelometry.
    Balla G; Misz M; Karmazsin L; Rák K
    Thromb Haemost; 1984 Feb; 51(1):9-11. PubMed ID: 6426081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative measurement of antithrombin III by latex agglutination and radial immunodiffusion in patients with peritonitis].
    Miagkova MA; Aleshkin AV; Abramenko TV; Savitskaia IuA; Aleshkin VA
    Klin Lab Diagn; 1997 Jan; (1):15-6. PubMed ID: 9091127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of plasma antithrombin III activity in healthy horses.
    Stephens KA; Morcom E; Hood DM
    Am J Vet Res; 1984 Feb; 45(2):351-3. PubMed ID: 6711961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laser nephelometric quantitation of antithrombin-III (AT-III) development of a new assay.
    Parvez Z; Fareed J; Messmore HL; Moncada R
    Thromb Res; 1981 Dec 1-15; 24(5-6):367-77. PubMed ID: 6806931
    [No Abstract]   [Full Text] [Related]  

  • 40. Cerebral venous thrombosis in nephrotic syndrome.
    Akatsu H; Vaysburd M; Fervenza F; Peterson J; Jacobs M
    Clin Nephrol; 1997 Nov; 48(5):317-20. PubMed ID: 9403217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.